fluorescent immunoassay

fluorescent immunoassay (FIA),

an immunoassay technique in which antigen or antibody is labeled with fluorescent dye.
Mentioned in ?
References in periodicals archive ?
The US Food and Drug Administration revealed on Tuesday that it has granted approval for to healthcare company Oxford Immunotec Inc's Imugen Babesia microti Arrayed Fluorescent Immunoassay (AFIA) for the detection of antibodies to Babesia microti (B.
In line with its strategy the company managed to receive regulatory approvals for several products such as AmpliVue Trichomonas Assay, Sofia Strep A+ Fluorescent Immunoassay, AmpliVue Bordetella Assay, Lyra Parainfluenza Assay and others.
He managed the development of the recently FDA-cleared and CLIA-waived Sofia[R] Fluorescent Immunoassay system with the associated Influenza A+B assay and is currently managing the development of a series of follow-on assays for the Sofia system.
Simultaneous measurement of thyroxine (T4) and thyrotropin (TSH) from newborn dried blood spot specimens using a multiplexed fluorescent immunoassay.
In addition, although almost all of the participants using immunoassays with a cutoff of 300 ng/mL detected the opiate hydromorphone at 1000 ng/mL, the many laboratories that used fluorescent immunoassay (FIA) and microparticle immunoassay (kinetic interaction of microparticles in solution) did not (UDS-A 2003) (Table 2).
NASDAQ: QDEL) has received 510(k) clearance and clinical laboratory improvements amendments (CLIA) waiver from the United States Food and Drug Administration for its Sofia RSV Fluorescent Immunoassay to be used with the Sofia 2 Fluorescent Immunoassay Analyzer for the rapid detection of respiratory syncytial virus (RSV) infections in nasopharyngeal swab and nasopharyngeal aspirate/wash specimens taken directly from symptomatic pediatric patients, the company said.
pneumoniae Fluorescent Immunoassay for use with the Sofia Fluorescent Immunoassay Analyzer
Simultaneous measurement of thyroxine (T4) and thyrotrophin (TSH) from newborn dried blood spot specimens using a multiplexed fluorescent immunoassay.
NASDAQ: QDEL) has received 510(k) clearance and Clinical Laboratory Improvements Amendments waiver from the United States Food and Drug Administration for Quidel's Sofia Influenza A+B Fluorescent Immunoassay to be used with the Sofia 2 Fluorescent Immunoassay Analyzer, the company said.
Diagnostic testing company Quidel (NASDAQ:QDEL) disclosed on Monday the receipt of the US Food and Drug Administration's (FDA) Clinical Laboratory Improvement Amendments (CLIA) waiver for its Sofia RSV Fluorescent Immunoassay (FIA) for the rapid detection of respiratory syncytial virus (RSV).
NASDAQ: QDEL) has received approval from Japan's Pharmaceuticals and Medical Devices Agency for the company's Sofia Influenza A+B Fluorescent Immunoassay to be used with the Sofia Fluorescent Immunoassay Analyzer, the company said.
Quidel (NASDAQ: QDEL), a healthcare company, has received FDA 510(k) approval for its Sofia hCG fluorescent immunoassay for use on the Sofia Analyzer, it was reported yesterday.

Full browser ?